Experimental studies suggested that metformin may alter gut microbiota composition as well as the BSH activity in patients with T2DM, thereby increasing some BAs that may antagonize intestinal FXR [2,16]. This evidence concerns the gene NR1H4 and type 2 diabetes mellitus.